IL17A and neoplasm: In a patient-derived GBM preclinical model, IL-17A inhibitors increased overall survival and decreased tumor growth/tumor hypoxia, angiogenesis, VEGF expression, cell proliferation, leptin expression and adipogenesis compared to control samples.